CANCER VACCINES 2003

Cancer & HIV Vaccines: Shared Lessons

On October 1-3, 2003 The Cancer Research Institute, in conjunction with the Academy of Cancer Immunology, sponsored CANCER VACCINES 2003-Cancer & HIV Vaccines: Shared Lessons. The meeting brought together over 350 leaders in the fields of cancer immunology and AIDS from around the globe. Since the researchers involved in the development of vaccines for both of these diseases do not often meet and share information, the CRI meeting provided such an opportunity and helped stimulate new ideas and collaborations that could benefit both fields. The meeting, which featured 19 plenary lectures and a poster session, focused on the development of therapeutic vaccines for each disease and highlighted the current state of efforts aimed at eliciting and monitoring the immunological responses to vaccines. 

Abstracts:

• Antonio Lanzavecchia. Vaccination and Immunological Memory. Institute for Research in Biomedicine, Bellinzona, Switzerland.
• Andrew McMichael, Jean Lee, Tao Dong, GuillaumeStewart-Jones, Yvonne Jones. HIV Vaccines: The Myth of Cross-Reactive T Cells. Weatherall Institute of Molecular Medicine, The John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
• Dennis R. Burton. Approaches to the Neutralizing Antibody Problem in HIV Vaccine Design. The Scripps Research Institute, La Jolla, CA.
• Thierry Boon, Pierre Coulie, Vaios Karanikas, Christophe Lurquin, Bernard Lethé, Wenbin Ma, Catherine Germeau. T-Cell Responses in Vaccinated Melanoma Patients. Ludwig Institute for Cancer Research, Brussels, Belgium, Unit of Cellular Genetics, University of Louvain, Louvain, Belgium.
• Gerold Schuler. Use of Monocyte-Derived Dendritic Cells in Cancer Immunotherapy. University Hospital, Erlangen, Germany.
• Ruslan Medzhitov. Toll Pathway of Host Defense. Yale University School of Medicine, New Haven, CT.
• Norman L. Letvin. AIDS Virus Escape From Cytotoxic T Lymphocyte Containment in Monkeys. Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA.
• Shimon Sakaguchi. Naturally Arising CD25+CD4+ Regulatory T Cells in Auto-Immunity and Tumor Immunity. Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan.
• Steven A. Rosenberg. Approaches to Cancer Immunotherapy Based on Breaking Tolerance to Non-Mutated Antigens Overexpressed on Metastatic Cancers. National Cancer Institute, Bethesda, MD.
• Philip D. Greenberg, Joseph Blattman, Laurence Cheng, Michelle Dossett, Carla Fowler, Yamina Hamel, William Ho, David Kranz*, Adrian Ochsenbein,  Claes Ohlen, Max Topp, Cassian Yee. Engineered T Cells as Reagents to Understand and Overcome the Limitations of Naturally- or Vaccine-Induced T-Cell Responses. University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; *University of Illinois, Urbana, IL
• Rafi Ahmed. Memory CD8 T-Cell Differentiation During Acute Versus Chronic Viral Infection. Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA.
• Jeffrey D. Lifson. Inactivated Retroviral Virions With Functional Envelope Glycoproteins. SAIC Frederick, Inc., National Cancer Institute, Frederick, MD.
• Alexander Knuth. Cancer Vaccination Strategies Targeting NY-ESO-1. University Hospital Zurich, Zurich, Switzerland.
• Sacha Gnjatic. Naturally Occurring Immunogenicity of NY-ESO-1 in Cancer Patients. Ludwig Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, NY.
• Elke Jäger. Vaccines Against NY-ESO-1: Peptides and Recombinant Viral Constructs. Krankenhaus Nordwest, Frankfurt, Germany.
• Jonathan Cebon. NY-ESO-1 Protein Formulated With ISCOMATRIX™ Adjuvant Induces a Broad-Based Immune Response Involving High Titers of Antibody, CD4+ and CD8+T-Cell Responses. Ludwig Institute for Cancer Research, Melbourne Victoria, Australia.

Ian D. Davis¹, Weisan Chen¹, Heather Jackson¹, Phillip Parente¹,², Catherine Barrow¹,², Wendie Hopkins¹, Qiyuan Chen¹, Roger Murphy¹, Andrew Scott¹,², Eugene Maraskovsky¹, Grant McArthur³, Duncan MacGregor², Tsin Yee Tai¹, Nektaria Dimopoulos¹, Simon Green⁴, Andrew Cuthbertson⁴, Darryl Maher⁴, Lena Miloradovic⁴, Sue Mitchell⁴, Gerd Ritter⁵, Elisabeth Stockert⁵, Lisa Pugliese⁵, Eric W. Hoffman⁵, Lloyd J. Old⁵. 

¹Ludwig Institute for Cancer Research, Melbourne ² Austin Hospital, ³ Peter MacCallum Cancer Centre, ⁴ CSL Limited, ⁵ Ludwig Institute for Cancer Research.

• Pramod K. Srivastava. Heat Shock Protein Receptors: Implications for Vaccination. University of Connecticut Health Center, Farmington, CT.
• Jean-Charles Cerottini, Pedro Romero, Daniel E. Speiser. Melan-A/MART-1: Immunogenicity and Vaccine Strategies. Ludwig Institute for Cancer Research, Lausanne, Switzerland.
• Vincenzo Cerundolo. Immunodominance of Pox-Viral Specific CTL and the Role of NKT Cells to Induce Broad Antigen-Specific CD4⁺ and CD8⁺T-Cell Responses: Lessons From Pre-Clinical and Clinical Studies. The John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
• Emilio A. Emini. A Potential HIV-1 Vaccine Based on the Elicitation of Cellular Immune Responses. Merck Research Laboratories, West Point, PA.